• Home
  •  / Mirati Therapeutics

Mirati Therapeutics

OverviewSuggest Edit

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

TypePublic
Founded2013
HQSan Diego, CA, USMap
Websitemirati.com
View Jobs (64)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)111(+77%)
Job Openings64
Revenue (FY, 2020)$13.4 M(+302%)
Share Price (Jun 2021)$158.7(+3%)
Cybersecurity ratingAMore

Key People/Management at Mirati Therapeutics

Charles M. Baum

Charles M. Baum

President and Chief Executive Officer, Director
Julie M. Cherrington

Julie M. Cherrington

Director
James Christensen

James Christensen

Executive Vice President and Chief Scientific Officer
Aaron I. Davis

Aaron I. Davis

Director
Reena Desai

Reena Desai

General Counsel and Corporate Secretary
Henry J. Fuchs

Henry J. Fuchs

Director
Show more

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego
San Diego, CA, US (HQ)
9393 Towne Centre Dr #200
Show all (1)

Mirati Therapeutics Financials and Metrics

Mirati Therapeutics Revenue

Mirati Therapeutics's revenue was reported to be $13.4 m in FY, 2020
USD

Net income (Q1, 2021)

(135.7m)

EBIT (Q1, 2021)

(132.4m)

Market capitalization (4-Jun-2021)

8.1b

Closing stock price (4-Jun-2021)

158.7

Cash (31-Mar-2021)

329.5m

EV

7.9b
Mirati Therapeutics's current market capitalization is $8.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

12.9m3.3m13.4m

General and administrative expense

11.1m12.7m15.8m15.3m13.5m21.7m42.6m83.4m

R&D expense

19.8m26.1m49.0m68.5m58.1m93.9m182.9m299.3m

Operating expense total

32.0m39.1m64.7m83.8m71.5m115.6m225.4m382.8m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

9.5m1.2m577.0k988.0k267.0k11.4m

General and administrative expense

2.4m3.7m2.4m2.9m3.5m3.8m4.2m4.2m4.1m3.8m3.5m3.7m3.7m3.1m5.2m4.8m5.3m9.8m9.9m10.7m18.0m19.8m20.2m28.4m

R&D expense

4.5m5.5m5.2m7.2m7.0m8.2m11.3m14.6m18.0m18.4m16.1m14.4m15.0m13.5m19.7m23.8m23.6m34.2m38.3m47.4m71.7m65.1m79.9m104.1m

Operating expense total

6.9m9.2m8.0m10.1m10.5m12.0m15.5m18.7m22.1m22.2m19.6m18.1m18.6m16.6m24.8m28.7m28.9m44.0m48.2m58.0m89.8m84.9m100.1m132.4m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

14.2m6.6m49.5m22.4m107.7m32.7m46.5m885.6m

Accounts Receivable

Prepaid Expenses

2.1m3.4m3.1m4.9m3.9m9.4m13.5m

Inventories

Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

9.7m7.6m8.3m8.5m4.9m14.3m13.4m109.9m34.6m24.5m19.8m29.8m20.0m20.8m20.6m106.0m116.7m74.6m252.1m91.9m204.5m131.7m131.4m329.5m

Accounts Receivable

66.0k

Prepaid Expenses

1.8m1.5m2.7m1.7m2.6m3.2m2.0m3.0m2.2m1.7m2.5m2.5m4.4m4.4m4.4m3.4m3.5m5.4m10.2m10.4m9.5m8.3m16.3m16.3m

Current Assets

22.4m17.0m56.0m49.2m40.3m71.2m60.9m141.0m109.9m93.0m75.5m107.9m92.3m79.4m153.1m263.6m246.1m306.4m495.7m464.6m704.8m654.0m595.4m1.3b
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(52.9m)(43.7m)(64.5m)(83.1m)(70.4m)(98.4m)(213.3m)(357.9m)

Depreciation and Amortization

171.0k199.0k212.0k180.0k184.0k175.0k249.0k

Accounts Payable

(68.0k)151.0k4.4m5.2m(1.3m)12.9m23.0m23.2m

Cash From Operating Activities

(29.5m)(32.7m)(50.7m)(68.0m)(64.7m)(70.1m)(147.7m)(271.5m)
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(12.2m)(41.6m)(13.7m)(24.7m)(33.3m)(11.9m)(27.4m)(46.1m)(21.9m)(44.0m)(63.4m)(17.8m)(36.2m)(52.5m)(14.7m)(42.6m)(70.1m)(40.9m)(86.6m)(140.9m)(86.7m)(169.5m)(256.8m)(135.7m)

Depreciation and Amortization

64.0k105.0k78.0k116.0k154.0k44.0k100.0k153.0k58.0k100.0k45.0k41.0k131.0k44.0k99.0k126.0k253.0k294.0k

Accounts Payable

(756.0k)1.3m(1.3m)649.0k111.0k(482.0k)1.7m4.4m1.0m4.0m3.8m(3.5m)(3.1m)(3.3m)2.7m4.9m8.6m(1.1m)2.1m9.3m6.9m8.8m17.3m4.4m

Cash From Operating Activities

(16.5m)(21.7m)(8.8m)(14.5m)(24.2m)(9.8m)(18.8m)(34.7m)(17.0m)(33.6m)(51.9m)(18.2m)(35.8m)(50.9m)(7.9m)(29.1m)(49.3m)(34.5m)(72.9m)(105.8m)(59.0m)(118.3m)(195.1m)(110.4m)
show all
USDQ2, 2013

Financial Leverage

3.7 x
Show all financial metrics

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued

32

Patents Pending

1
Show all operating metrics

Mirati Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Mirati Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Mirati Therapeutics Online and Social Media Presence

Mirati Therapeutics's Trends

Embed Graph

Mirati Therapeutics News and Updates

June 01, 2021

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

SAN DIEGO and SHANGHAI and SAN FRANCISCO, June 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the...
April 10, 2021

Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models

SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational synthetic lethal PRMT5 inhibitor in methylthioadenosine phosphorylase (MTAP)-deleted...
March 31, 2021

Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director

SAN DIEGO, March 31, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director, Ms. Shalini Sharp. "I am pleased to welcome Shalini to our Board during a...
January 04, 2021

Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11th at 12:40 p.m. PST/ 3:40 p.m. EST. Charles M. Baum, M.D.,...
November 05, 2020

Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m....
November 04, 2020

Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights. "The third quarter was notable for significant...
Show more

Mirati Therapeutics Blogs

April 01, 2019

Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference

Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference Content Import Mon, 04/01/2019 - 16:36 Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference April 1, 2019 This release i…
February 28, 2019

Mirati Therapeutics Reports Fourth Quarter Financial Results

Mirati Therapeutics Reports Fourth Quarter Financial Results Content Import Thu, 02/28/2019 - 16:26 Mirati Therapeutics Reports Fourth Quarter Financial Results February 28, 2019 This release is a backfill from a News Wire Earnings …
February 19, 2019

Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors

SAN DIEGO , Feb. 19, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019 . Dr. Rodney Lappe Ph.D.
February 07, 2019

Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14 th at 11:00 a.m. ET / 8:00 a.m. PT .
January 22, 2019

Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

SAN DIEGO , Jan. 22, 2019 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62 .00 per share.
January 16, 2019

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock Content Import Wed, 01/16/2019 - 16:04 Mirati Therapeutics Announces Proposed Public Offering Of Common Stock January 16, 2019 This release is a backfill from a News Wire Ge…
Show more

 Mirati Therapeutics Frequently Asked Questions

  • When was Mirati Therapeutics founded?

    Mirati Therapeutics was founded in 2013.

  • Who are Mirati Therapeutics key executives?

    Mirati Therapeutics's key executives are Charles M. Baum, Julie M. Cherrington and James Christensen.

  • How many employees does Mirati Therapeutics have?

    Mirati Therapeutics has 111 employees.

  • What is Mirati Therapeutics revenue?

    Latest Mirati Therapeutics annual revenue is $13.4 m.

  • What is Mirati Therapeutics revenue per employee?

    Latest Mirati Therapeutics revenue per employee is $120.7 k.

  • Who are Mirati Therapeutics competitors?

    Competitors of Mirati Therapeutics include OncoStem Diagnostics, 3sbio and Takeda Oncology.

  • Where is Mirati Therapeutics headquarters?

    Mirati Therapeutics headquarters is located at 9393 Towne Centre Dr #200, San Diego.

  • Where are Mirati Therapeutics offices?

    Mirati Therapeutics has an office in San Diego.

  • How many offices does Mirati Therapeutics have?

    Mirati Therapeutics has 1 office.